GEN-MKT-18-7897-A
Aug 10, 2016 | Blogs, Forensic | 0 comments
How do you know what you can’t see? This is the challenge many a lab faces as they relentlessly test for novel psychoactive substances (NPS) as unknown samples with an ever-changing ingredient list make discovery difficult work at best. There are many reasons for the complexities of which you can discover in this application note, “Accurate Mass Screening Workflows for the Analysis of Novel Psychoactive Substances.” However, the biggest of which is that non-targeted findings can turn up thousands of molecular features in a single sample. Sifting through the peaks is laborious, and many are normal besides.
Therefore, in this application note, our researchers took a comparative screening approach to NPS by testing urine samples against a control group using high resolution and accurate mass LC-MS/MS. The TripleTOF® system was then operated in IDA mode to acquire MS and MS/MS information simultaneously.Using this method reduced the compound list from thousands to just 10. Now that is a much more manageable sample size for which to analyze peak findings.
Application Note Overview:
Be confident in your NPS sample. Review the application note in its entirety.Download the Designer Forensic Drug Analysis Solution Kit >
Finding the right information shouldn’t slow you down. Whether you’re troubleshooting your mass spec, learning something new, or optimizing performance, access to the right resources at the right moment makes all the difference.
As an analytical strategy, middle-down mass spectrometry (MS) workflows characterize biotherapeutic proteins by analyzing large, digested protein fragments or defined subunits, rather than fully intact proteins (top-down) or digested peptides (bottom-up). A middle-down strategy combines the strengths of top-down and bottom-up approaches by delivering high sequence coverage and structural specificity while maintaining relatively simple sample preparation. In practice, middle-down analysis enables accurate mass measurement, rapid sequence confirmation, and localization of key post-translational modifications (PTMs) on protein subunits that are directly relevant to product quality.
In biopharmaceutical development, sequence variants (SV) are considered an inherent risk of producing complex proteins in living systems. Sequence variants are unintended changes to the amino acid sequence of a biotherapeutic and can be caused by errors in transcription or translation in the host cell, or cell culture and process conditions. Detailed analysis of SVs is important in process and product development to ensure the drug’s safety and efficacy. Even low‑level sequence variants can have significant implications for product quality, safety, and efficacy, making their accurate detection and characterization a critical requirement across development, process optimization, and regulatory submission.
Posted by
You must be logged in to post a comment.
Share this post with your network